As Malaria Vaccine Research Goes On, Continue To Support Existing Prevention Tools To Save Lives

In this Huffington Post opinion piece, Tido von Schoen-Angerer, executive director of the Doctors Without Borders Access to Essential Medicines Campaign, responds to the results of the RTS,S malaria vaccine clinical trial announced last week, writing, “A malaria vaccine that works would be a major breakthrough. But while the latest advance toward the development is scientifically important, there are several reasons to be cautious about the difference this vaccine could make, on the basis of current results.”

Von Schoen-Angerer writes that protection from the vaccine is low by international standards and potentially only short-term. “So while research must continue to see whether we can improve these results, the important point right now is to continue fighting malaria with all the other tools we know work — prevention tools like bed nets and insecticides, tests to help rapidly diagnose disease and, most importantly, treatment that works to save lives” (10/24).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.